Cipla Analyst Review May 2026

This Cipla analyst review for May 2026 covers the key data investors need for CIPLA at its current price of Rs 1,680. Cipla (NSE: CIPLA) is one of India’s largest pharmaceutical companies with a market capitalisation of approximately Rs 1,36,000 crore, known for its respiratory portfolio and branded generic presence across 80 plus countries. The analyst consensus target of Rs 1,900 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether CIPLA achieves that target through FY27.

Click Here – Get Free Investment Predictions

Cipla Company Snapshot May 2026

Cipla’s branded specialty businesses in India, South Africa, and the US are growing at 15 to 20 percent. The specialty CNS products partnership and ANDA filings for complex generics in the US are catalysts for FY27 and beyond. The table below summarises the key data referenced in this Cipla analyst review.

Parameter	Value
NSE Ticker	CIPLA
Sector	Pharmaceuticals
CMP (May 2026)	Rs 1,680
52 Week High	Rs 1,790
52 Week Low	Rs 1,350
Market Cap	Rs 1,36,000 Crore
Trailing P/E	28.00x
Analyst Consensus Target	Rs 1,900
Bull Case Target	Rs 2,200
Bear Case Target	Rs 1,400

Analyst Insight in This Cipla Analyst Review

Senior Research Analyst Ankit Jaiswal flags Cipla as a stock to watch in May 2026. At Rs 1,680, Ankit Jaiswal notes that the key levels for CIPLA include support in the Rs 1,377 to Rs 1,596 band and resistance near Rs 1,781. He suggests watching Cipla for a potential move toward the consensus target of Rs 1,900, contingent on Pharmaceuticals sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Cipla analyst review and does not constitute a trade recommendation.

Technical Analysis in This Cipla Analyst Review

At Rs 1,680, CIPLA is trading within its 52-week band of Rs 1,350 to Rs 1,790. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 1,377 to Rs 1,596 band while resistance is seen in the Rs 1,781 to Rs 1,790 zone. A sustained move above Rs 1,781 could open the path toward the analyst consensus of Rs 1,900.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 1,377 to Rs 1,596 – investors tracking this Cipla analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
• Resistance Zone: Rs 1,781 to Rs 1,790 – a sustained close above Rs 1,781 would be a positive breakout signal worth flagging.
• Medium-Term Target: The analyst consensus of Rs 1,900 represents the base-case upside for this Cipla analyst review.

Business Segment Analysis

India Branded Generics (Respiratory, Cardiology, Oncology)

This is the primary revenue and margin driver for Cipla, directly supporting the earnings trajectory toward the consensus target of Rs 1,900.

US Generics (Complex Inhalers and Injectables)

This segment adds scale and diversification to Cipla’s business model and is a meaningful EPS contributor through FY27 and FY28.

South Africa and Sub-Saharan Africa Branded Business

This represents the medium-term growth frontier for Cipla and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Cipla Analyst Review

At Rs 1,680, Cipla trades at a trailing P/E of 28.00x. This Cipla analyst review presents three scenarios: a bull case of Rs 2,200 on strong earnings delivery, a base case of Rs 1,900 at consensus, and a bear case of Rs 1,400 if macro headwinds persist. Q1 FY27 results will be the first key validation point.

Scenario	Target Price	Key Condition
Bull Case	Rs 2,200	Strong earnings and sector tailwinds
Base Case (Consensus)	Rs 1,900	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,400	Earnings miss or macro headwinds

Trade Outlook for Cipla

Based on the technical and fundamental analysis in this Cipla analyst review, investors might watch CIPLA near the support zone of Rs 1,377 to Rs 1,596 for potential opportunities. A flag above Rs 1,781 could suggest improving momentum toward Rs 1,900. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Cipla in FY27

A well-rounded Cipla analyst review must assess downside risks. Key risks for Cipla include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in CIPLA.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Cipla Analyst Review Verdict for 2026

This Cipla analyst review concludes that at Rs 1,680, CIPLA offers a defined risk-reward with a consensus target of Rs 1,900. The 52-week range of Rs 1,350 to Rs 1,790 provides context on the current entry point. Use this Cipla analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on CIPLA.

Frequently Asked Questions: Cipla Analyst Review 2026

What is the analyst target for Cipla in 2026?

The analyst consensus target is Rs 1,900, with a bull case of Rs 2,200 and a bear case of Rs 1,400. Monitor Q1 FY27 earnings for confirmation.

Is Cipla a good investment at Rs 1,680?

At Rs 1,680 with a P/E of 28.00x and a consensus target of Rs 1,900, this Cipla analyst review is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.

What is Cipla’s 52-week high and low?

The 52-week high is Rs 1,790 and the 52-week low is Rs 1,350. At Rs 1,680, CIPLA is positioned within this range as noted in this Cipla analyst review.

What are the key risks for Cipla?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.

Where can I get live data and analyst targets for Cipla?

Track Cipla’s live price and analyst targets on the Univest Screener alongside professional financial advice.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.